

ELMMB Formulary Update

February 2019

Subscribe Now

And be one of the first to know...

BLACK traffic Light - not recommended for prescribing in primary or secondary care.

- **Cannabis-based medicinal products in chronic pain** – not recommended
- **Darvadstrocel** – treatment of complex perianal fistulas / Crohn's disease – not recommended by [NICE TA556](#)

RED traffic light - Primary care prescribers should not be asked to prescribe (** denotes NHS England Commissioned)

- **Gastrografin**® - contrast medium for use in bowel obstruction by senior clinician.
- **Pembrolizumab** with pemetrexed and platinum chemotherapy – for untreated, metastatic, non-squamous non-small-cell lung cancer – an option in [NICE TA557](#)
- **Palacos R+G Fast** – bone cement with gentamicin for use in orthopaedic procedures (replaces CMW 2G on formulary)
- **Nivolumab** – adjuvant treatment of completely resected melanoma with lymph node involvement in metastatic disease – an option in [NICE TA558](#)
- **Pirenzepine** – unlicensed use for clozapine hypersalivation.
- **Regorafenib**** – previously treated advanced hepatocellular carcinoma- an option in [NICE TA555](#)
- **Axicabtagene ciloleucel** – for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies – an option in [NICE TA559](#)

AMBER Traffic Light - initiated by specialists but may then be passed to primary care for prescribing

- **Ciclesonide inhaler** (Alvesco®) – an option in asthma for those who continue to have exacerbations despite other step 4 therapies
- **Brivaracetam** (Briviact®) – switched to AMBER – now licensed for use in adults, adolescents and children from 4 years of age
- **Gentamicin** for nebulisation – recommended by BTS for non CF bronchiectasis in adults. (2nd line alternative to colistin)

GREEN Traffic Light - may be prescribed by all prescribers within local or national recommendations

- **Norgestimate 250mcg & Ethinylestradiol 35mcg** (Cilique®) added to formulary to replace Cilest® which is being discontinued.
- **Abidec and Sytron for premature neonates** – prescribing to be continued in Primary Care up to 12 months of age.
- **Ganciclovir eye ointment** – added to formulary to replace aciclovir eye ointment which is being discontinued (NOTE: ganciclovir eye oint is not licensed in children under the age of 18 years)
- **Epimax® paraffin free ointment** – an option where paraffin free emollient is required.
- **Vortoxetine** - Major depressive episodes in adults whose conditions has responded inadequately to 2 antidepressants.

Guidelines/Other

- [Medicines Management Board Minutes](#)
- [Drug Safety Updates](#)
- [Nice Bites](#)
- [Prescribing Hot Topics](#)
- [New PrescQipp e-learning:](#)
 1. [Anticholinergic burden](#)
 2. [Reducing Opioid Prescribing in chronic pain](#)
- [Training for Care Home Staff](#)
- [LMWH Best Practice Guidance – updated to reflect use of enoxaparin \(Inhixa® brand\) for prophylaxis by the ELHT](#)
- [Shared Care Guidelines](#)
- [Cannabis-based Medicinal Products for Chronic Pain Position Statement](#)
- [Goserelin \(Zoladex®\) Shared Care Guidelines – approved for use in ELHE](#)
- [Cytotoxics – Guidance for Care Homes and Nursing Homes](#)
- [Asthma Treatment Guidelines for Adults](#)